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In this work GPI binding to membrane proteins from erythrocytes of insulinoma pa-
tients for whom prolonged hyperinsulinism and hypoglycemia were characteristic, as well
as from normal erythrocytes incubated with supraphysiological concentrations of insulin
were analyzed. In the RBCs from insulinoma patients, covalent GPI binding to red cell
membrane proteins in the spectrin/ankyrin region, band 4.1 and two proteins of molecular
mass of 115 and 110 kD was demonstrated. In erythrocytes incubated with insulin label was
associated with band 4.1 and two proteins of molecular mass of 115 and 110 kD. Extraction
studies showed that the 100-kD proteins are unrelated to band 3 since they were found in Tri-
ton-prepared cytoskeleton. To our knowledge this is the first demonstration of such a modifi-
cation of red cell skeletal proteins, and the first demonstration of post-translation GPI bind-
ing to red cell skeletal proteins in response to insulin. A mechanism proposed for GPI bind-
ing to red cell skeletal proteins as well as the relevance of these results for physiological dis-
orders that are characterized by hyperinsulinism are briefly discussed.
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INTRODUCTION
Glycosylphosphatidylinositol (GPI) is a complex glycolipid that is covalently at-
tached to surface proteins of many eukaryotic cells: GPI provides an alternative anchoring
mechanism to a hydrophobic polypeptide transmembrane domain, enabling stable associ-
ation of protein with the lipid bilayer.1,2 In addition to GPI-anchors, free GPI units are also
expressed in eukaryotic cell membranes.3 The majority of these free GPIs are found at the
outer surface in a variety of cell types thus far studied.4 Insulin stimulates hydrolysis of
both GPI-anchors5–7 and free GPIs.4 Phosphoinositolglycans and diacylglycerol derived
from free GPIs through the action of insulin-activated phospholipase C were proposed as
second messengers of insulin.8
Human erythrocytes (RBC) contain highly specific insulin receptors that have struc-
tural and functional characteristics similar to those of target tissues for the action of the hor-
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mone.9 Free GPI-lipids from erythrocyte membranes are, as opposed to other cell types,
largely cytoplasmatically oriented and insensitive to insulin-induced hydrolysis.4 We
found that exposure of RBC to supraphysiological concentrations of insulin, both in vivo
and in vitro, caused covalent glycoinositolphospholipid (GPI) binding to C termini of both
hemoglobin (Hb) -chains which resulted in the formation of a novel, hitherto unrecog-
nized minor Hb fraction (GPI-Hb) (ca. 4 % of total Hb).10
By applying the same approach and methods our studies were extended in this work
to insulin-induced binding of GPI to red cell membrane proteins. Both, red cell membrane
proteins from (six) patients with diagnosed insulinoma, for whom chronic hyperinsulinism
and hypoglycemia were characteristic,10 and from normal erythrocytes incubated with
supraphysiological concentrations of insulin were analyzed. In the RBCs from insulinoma
patients, covalent GPI binding to red cell membrane proteins in the spectrin/ankyrin re-
gion, band 4.1 and two proteins of molecular mass of 115 and 110 kD was demonstrated.
In erythrocytes incubated with insulin, the label was associated with band 4.1 and two pro-
teins of molecular mass of 115 and 110 kD. To our knowledge this is the first demonstra-
tion of such a modification of red cell skeletal proteins, as well as the first demonstration of
post-translational GPI binding to red cell skeletal proteins in response to insulin.
RBC membrane proteins were resolved by SDS-PAGE11 and GPI-modified proteins
were identified by overlaying the Coomassie Blue-stained gel on immunoblots obtained
by using anti CRD antibodies from polyclonal rabbit antisera raised against soluble form of
a variant surface glycoproteins (sVSG).12 The treatment of GPIs with PI-specific pho-
spholipase C (PI-PLC) exposes a carbohydrate epitope known as the cross-reacting deter-
minant (CRD). Anti CRD antibody reacts to a large extent with inositol 1,2-cyclic phos-
phate epitope (produced by PI-PLC cleavage), and (to a lesser extent) with other GPI
epitopes including non-acetylated glucosamine.13 Thus, detection of the CRD epitope al-
lows the unambiguous assignment of the presence of a GPI anchor on a particular pro-
tein.12,13 Indeed, immunoblotting of a PI-PLC-treated membrane form of VSG (mfVSG)
and untreated sVSG gave intensive reaction with anti CRD antibody (results not shown).
This is expected for the quantitative binding of anti-CRD antibodies, which requires the
presence of all structural elements of the GPI structure. Fig. 1 shows that for GPI-labeled
RBC membrane proteins low, but diagnostically significant reaction with the antibody,
which did not increase in the PI-PLC treated samples (results not shown) was obtained.
This points to the esterification of inositol with palmitic acid, which was shown to make
the GPI-anchor resistant towards PI-PLC.14
Immunoblots of membrane proteins from control RBC samples show the presence of
bands in the 70 kD region, which may be affiliated to the well-known endogenous red cell
GPI proteins such as acetylcholinesterase monomer, (Mw 68 kD) and decay accelerating
factor (DAF, Mw 70 kD)16,17 (Fig. 1. line C). For RBCs from insulinoma patients the of
GPI binding to red cell membrane proteins in the spectrin/ankyrin region band 4.1 and two
proteins of molecular mass of 115 and 110 kD was characteristic (Fig. 1. line P). GPI bind-
ing in the spectrin/ankyrin region is due to spectrin band 2 and spectrin 1 band or ankyrin
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which, in this gel system, migrates with or, sometimes, above the spectrin 1 band.18 In red
cell membrane from erytrocytes of normal healthy volunteers incubated with insulin label
binding was associated with band 4.1 and two proteins of molecular mass of 115 and 110
kD (Fig. 1, line 1).
To further characterize the GPI-labeled proteins in insulin-treated red cells, the ghosts
were extracted with cold Triton X-100.19 Extraction with Triton X-100 at 4 ºC solubilizes
band 3 and the bulk of the glycophorins whereas most skeletal proteins20 and GPI-ancho-
red proteins, which, similarly to other cell types are clustered in lipid rafts,19 resist extrac-
tion by Triton X-100. Figure 1 (line T) shows that both endogenous GPI-anchored proteins
and all insulin-induced GPI-labeled RBC membrane proteins were present in the Triton
X-100 pellet. The amount of protein staining in the 100 kD area after Triton X-100 extrac-
tion is minimal,18 which demonstrates that the GPI-labeled 100 kD proteins are clearly un-
related to band 3. Although the 100 kD proteins are minor proteins in terms of amount,
they are probably the most highly GPI-labeled species in red cell membranes following
their exposure to insulin, as the label incorporated into them was about equivalent to that
incorporated into the much more abundant band 4.1 (Fig. 1, lines I, P and T).
The pattern of insulin-induced GPI-labeling seen here, i.e., GPI-labeling of characteris-
tic red cell skeletal proteins, is similar to the pattern of protein kinase C-induced phospho-
rylation of red cell skeletal proteins.18,21 The major substrates for kinase in these studies were
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Fig. 1. Cross-reactivity of red cell mem-
brane proteins with anti CRD antibody.
Membranes isolated15 from the erythro-
cytes of patients with diagnosed insu-
linoma, for whom chronic hyperinsu-
linism and hypoglycemia were charac-
teristic, and from the erythrocytes of no-
rmal healthy volunteers incubated with
1 g insulin/ml at 37 ºC for 3 h,10 were
analyzed. RBC membrane proteins (30
g) were resolved by SDS-PAGE11 and
then transferred to a polivinylidendiflu-
oride (PVDF) membrane. The strip of
the blot was incubated with anti-rabbit
sVSG antiserum, and the cross reacted
primary antibodies were visualized with
a second alkaline phosphatase conjuga-
ted antibody. Anti CRD antibodies,
Pl-PLC, mfVSG and sVSG (which we-
re used to verify the detection reagents
and system) were all from Oxford Gly-
cosystem. Molecular masses were de-
termined by calibration of the gels using
red cell membrane proteins. The imunoblots detecting GPI labeling in control membranes (line C), mem-
branes from insulinoma patients (line P) and membranes from cells treated with insulin before (line I) and af-
ter extraction with 1 % Triton X-100 as described in Civenni et al.18 (line T) were shown.
also two ill-defined skeletal proteins of 100 kD.18,21 It would be of considerable interest to
identify and determine the function of these two proteins present in the erythrocyte skeleton.
It is well documented that addition of GPI anchors to proteins which occurs soon after
completion of polypeptide synthesis and translocation involve transamidase-catalyzed re-
action mechanism.22 GPI-transamidase represents a novel multi-subunit enzyme that re-
moves the carboxy-terminal signal sequence and attaches a GPI molecule to the newly ex-
posed carboxy terminal amino acid.23,24 Our recent studies show that formation of
GPI-Hb is associated with insulin-induced transpeptidase-like activity in the RBC mem-
brane (unpublished observation). The membrane skeletal proteins, which underlie the lipid
bilayer and are associated to it by protein-protein and protein-lipid interactions,25,26 come
in close contact with free GPI-lipids from the erythrocyte membrane which are largely
cytoplasmatically oriented.4 This permits the ethanolamine from GPI to come in close
contact with the C-terminal part of the polypeptide chains of skeletal proteins, which were
found to be GPI-modified. Insulin-activated transamidase in RBC membrane then catalyze
slowly the transpeptidation, i.e., the replacement of the carboxy-termal amino acid(s) resi-
dues of the polypeptide chains with GPI as an exogenous nucleophile.
The results described in the present work may have relevance to studies of physiologi-
cal disorders that are characterized by hyperinsulinism.27–29 GPI-anchoring of RBC skele-
tal poteins to the lipid bilayer will cause increased association of the red cell skeletal net-
work with plasma membrane, which is expected to have a profound effect on RBC
deformability and stability.30 This may, at least partly, explain the decrease of both RBC
membrane fluidity and deformability, which were found previously to be characteristic for
hyperinsulinism.27–29 A GPI adduct of Hb31 and GPI-labeled skeletal proteins (data not
shown) could be detected even 30 days after pancreotomy. The detection and monitoring
of chronic hyperinsulinism could be improved and/or facilitated by a means of identifying
the existence (and consequently levels) of the GPI adducts of red cell proteins.
GPI addition to RBC proteins in response to insulin may be relevant to other cell types
as well. In a previous in vitro study of Lisanti5 it was noted that insulin-induced release of
GPI-anchored proteins from cell membrane was followed by their recovery upon pro-
longed insulin exposure.5 The present results may be relevant to both the GPIs turnover in
insulin action,8 and the role suggested insulin plays in the regulation of GPIs in cell mem-
brane.5 Human erythrocytes, which represent an extremely useful and easily accessible
cellular model for the study of a variety of proteins, seem to be well suited for studying the
insulin-induced GPI-addition to proteins.
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I Z V O D
VEZIVAWE GLIKOZILFOSFATIDILINOZITOLA (GPI-a) ZA MEMBRANSKE
PROTEINE ERITROCITA POD DEJSTVOM INSULINA
NENAD TOMA[EVI], MILAN NIKOLI] i VESNA NIKETI]*
Hemijski fakultet, Univerzitet u Beogradu, Studentski trg 12-16, p. pr. 158, 11001 Beograd
U ovom radu ispitivano je vezivawe GPI-a za membranske proteine eritrocita pacijenata
obolelih od insulinoma, za koje su karakteristi~ni dugotrajni hiperinsulinizam i hipogli-
kemija, kao i u normalnim eritrocitima inkubiranim sa suprafiziolo{kim koncentra-
cijama insulina. Na|eno je da u eritrocitima pacijenata dolazi do kovalentnog vezivawa
GPI-a za membranske proteine eritrocita i to u oblasti spektrina i ankirina, za traku 4.1. i
dva proteina molekulskih masa 115 i 110 kD. U eritrocitima inkubiranim sa insulinom GPI se
vezuje za traku 4.1. i dva proteina molekulskih masa 115 i 110 kD. Utvr|eno je da proteini mase
100 kD ne poti~u od trake 3, jer su detektovani u citoskeletnoj frakciji zaostaloj posle
ekstrakcije membranskih proteina rastvorom Triton-a. U ovom radu je prvi puta detektovana
modifikacija citoskeletnih proteina eritrocita vezivawem GPI-a, kao i post-translaciono
vezivawe GPI-a za citoskeletne proteine eritrocita pod uticajem insulina. Ukratko je
diskutovan mehanizam vezivawa GPI-a za proteine citoskeleta eritrocita, kao i zna~aj
dobijenih rezultata za razumevawe fiziolo{kih poreme}aja u hiperinsulinizmu.
(Primqeno 10. jula 2002)
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